Literature DB >> 23810854

Development of an enzyme-linked immunosorbent assay based on the murine leukemia virus p30 capsid protein.

Dai-Tze Wu1, Sriram Aiyer, Rodrigo A Villanueva, Monica J Roth.   

Abstract

Retroviral vectors derived from the murine leukemia virus (MuLV) are widely used as the starting material in the development of vectors for gene therapy and critical in answering questions relating to viral pathogenesis. The p30 capsid (CA) is the major viral core protein and an internal group antigen in MuLV. In this study, an enzyme-linked immunosorbent assay (ELISA) was developed for quantitation of MuLV infectious particles with p30 CA core antigen protein. The ELISA was developed using several goat-polyclonal serum against MuLV p30 generated by the NCI as primary antibody and a rat-monoclonal antibody to CA available from ATCC. The MuLV p30 CA antigen was standardized against recombinant MuLV p30 CA expressed from bacteria. The assay is sensitive, accurate and linear within a defined concentration range of CA. Comparison with different MuLV quantitative methods including reporter gene transfer, reverse transcriptase activity assay, and viral RNA quantitative PCR, showed this ELISA protocol to be highly quantifiable within defined ranges, which can be correlated with infectious viral titer.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  MuLV CA ELISA; Virus normalization; p30 CA

Mesh:

Substances:

Year:  2013        PMID: 23810854      PMCID: PMC3775985          DOI: 10.1016/j.jviromet.2013.06.020

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  11 in total

1.  A gene therapy approach for treating T-cell-mediated autoimmune diseases.

Authors:  C Chen; A Rivera; N Ron; J P Dougherty; Y Ron
Journal:  Blood       Date:  2001-02-15       Impact factor: 22.113

2.  Quantitation of MLV-based retroviral vectors using real-time RT-PCR.

Authors:  M Carmo; C Peixoto; A S Coroadinha; P M Alves; P E Cruz; M J T Carrondo
Journal:  J Virol Methods       Date:  2004-08       Impact factor: 2.014

3.  Interactions of retroviral structural proteins with single-stranded nucleic acids.

Authors:  R L Karpel; L E Henderson; S Oroszlan
Journal:  J Biol Chem       Date:  1987-04-15       Impact factor: 5.157

4.  MuLV IN mutants responsive to HDAC inhibitors enhance transcription from unintegrated retroviral DNA.

Authors:  William M Schneider; Dai-tze Wu; Vaibhav Amin; Sriram Aiyer; Monica J Roth
Journal:  Virology       Date:  2012-02-23       Impact factor: 3.616

5.  Isolation and properties of Moloney murine leukemia virus mutants: use of a rapid assay for release of virion reverse transcriptase.

Authors:  S Goff; P Traktman; D Baltimore
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

6.  A transient three-plasmid expression system for the production of high titer retroviral vectors.

Authors:  Y Soneoka; P M Cannon; E E Ramsdale; J C Griffiths; G Romano; S M Kingsman; A J Kingsman
Journal:  Nucleic Acids Res       Date:  1995-02-25       Impact factor: 16.971

7.  Neuronal differentiation and growth control of neuro-2a cells after retroviral gene delivery of connexin43.

Authors:  A J Mao; J Bechberger; D Lidington; J Galipeau; D W Laird; C C Naus
Journal:  J Biol Chem       Date:  2000-11-03       Impact factor: 5.157

8.  Mutational analysis of the N-linked glycosylation sites of the SU envelope protein of Moloney murine leukemia virus.

Authors:  R H Felkner; M J Roth
Journal:  J Virol       Date:  1992-07       Impact factor: 5.103

9.  Characterization of monoclonal antibodies reactive with murine leukemia viruses: use in analysis of strains of friend MCF and Friend ecotropic murine leukemia virus.

Authors:  B Chesebro; W Britt; L Evans; K Wehrly; J Nishio; M Cloyd
Journal:  Virology       Date:  1983-05       Impact factor: 3.616

10.  Class II integrase mutants with changes in putative nuclear localization signals are primarily blocked at a postnuclear entry step of human immunodeficiency virus type 1 replication.

Authors:  Richard Lu; Ana Limón; Eric Devroe; Pamela A Silver; Peter Cherepanov; Alan Engelman
Journal:  J Virol       Date:  2004-12       Impact factor: 5.103

View more
  7 in total

1.  Repression of the Chromatin-Tethering Domain of Murine Leukemia Virus p12.

Authors:  Jonathon D Brzezinski; Apexa Modi; Mengdan Liu; Monica J Roth
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

2.  Phosphorylation Requirement of Murine Leukemia Virus p12.

Authors:  Jonathon D Brzezinski; Roland Felkner; Apexa Modi; Mengdan Liu; Monica J Roth
Journal:  J Virol       Date:  2016-11-28       Impact factor: 5.103

3.  Role of Cysteines in Stabilizing the Randomized Receptor Binding Domains within Feline Leukemia Virus Envelope Proteins.

Authors:  Leonardo Valdivieso-Torres; Anindita Sarangi; Jillian Whidby; Joseph Marcotrigiano; Monica J Roth
Journal:  J Virol       Date:  2015-12-30       Impact factor: 5.103

4.  MLV based viral-like-particles for delivery of toxic proteins and nuclear transcription factors.

Authors:  Dai-Tze Wu; Monica J Roth
Journal:  Biomaterials       Date:  2014-07-03       Impact factor: 12.479

5.  Structural and sequencing analysis of local target DNA recognition by MLV integrase.

Authors:  Sriram Aiyer; Paolo Rossi; Nirav Malani; William M Schneider; Ashwin Chandar; Frederic D Bushman; Gaetano T Montelione; Monica J Roth
Journal:  Nucleic Acids Res       Date:  2015-05-12       Impact factor: 16.971

6.  Disrupting MLV integrase:BET protein interaction biases integration into quiescent chromatin and delays but does not eliminate tumor activation in a MYC/Runx2 mouse model.

Authors:  Lorenz Loyola; Vasudevan Achuthan; Kathryn Gilroy; Gillian Borland; Anna Kilbey; Nancy Mackay; Margaret Bell; Jodie Hay; Sriram Aiyer; Dylan Fingerman; Rodrigo A Villanueva; Ewan Cameron; Christine A Kozak; Alan N Engelman; James Neil; Monica J Roth
Journal:  PLoS Pathog       Date:  2019-12-09       Impact factor: 6.823

7.  Gene delivery in a mouse xenograft of a retargeted retrovirus to a solid 143B osteosarcoma.

Authors:  Xia Zhang; Anindita Sarangi; Dai-Tze Wu; Jaya Kanduri; Monica J Roth
Journal:  Virol J       Date:  2013-06-14       Impact factor: 4.099

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.